Maurizio Fazio is a principal at Atlas Venture where he focuses on building companies that transform patient care by translating innovative science and technologies into novel therapeutics.

Prior to joining Atlas, Maurizio completed his PhD in biological and biomedical sciences at Harvard University. His doctoral work in the lab of Dr. Leonard Zon focused on identifying genetic and epigenetic drivers of melanoma progression towards metastasis and drug resistance. While in graduate school, Maurizio was a fellow at Vida Ventures and Flagship Pioneering, and served as HILT Education Innovation Fellow mentoring student-led startups from Harvard & MIT. In addition, he was an instructor at the Harvard Summer School, where he developed and taught courses on cancer biology, regenerative medicine, and gene therapy.

Before moving to Boston, Maurizio was a research fellow in the lab of Dr. Scott Armstrong at Memorial Sloan Kettering Cancer Center in New York, investigating novel epigenetic therapies for pediatric leukemia. His research work was supported by the Boehringer Ingelheim Fonds, the American Italian Cancer Foundation, the Armenise Harvard Foundation, and the European Association for Cancer Research. He received his MD cum laude with honor mention from Vita-Salute San Raffaele University in Milan, Italy.

Maurizio grew up in Sicily in a family of winemakers. In his free time, he enjoys sharpening his amateur chef skills, traveling the world, and going on diving adventures with his partner Ellen.